Literature DB >> 6498066

Oral contraceptive use and malignant melanoma in Australia.

V Beral, S Evans, H Shaw, G Milton.   

Abstract

In a case control study of 287 women aged 15-24 years with malignant melanoma and 574 matched controls, findings relating to oral contraceptive use and other hormone use are reported. Ever having used oral contraceptives was not associated with an increased risk of melanoma (relative risk for ever use of the pill = 1.0). Women with melanoma were, however, more likely to have taken oral contraceptives for long periods of time in the past, the relative risk associated with oral contraceptive use for a total duration of 5 years or longer which had begun at least 10 years before the melanoma was diagnosed being 1.5 (95% confidence interval 1.03 to 2.14) This elevated risk persisted after controlling for the reported hair and skin colour, frequency of moles on the body, place of birth, and measures of sunlight and fluorescent light exposure. Cases were more likely than controls to have used hormones to regulate their periods, hormonal replacement therapy and be given hormone injections to suppress lactation, the respective relative risks being 1.9, 1.4 and 1.4, but none differed significantly from 1.0. These findings suggest that prolonged oral contraceptive use may, after a lag of 10 years or so, increase the risk of malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6498066      PMCID: PMC1976969          DOI: 10.1038/bjc.1984.236

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  6 in total

1.  Oral contraceptive use and malignant melanoma.

Authors:  C Bain; C H Hennekens; F E Speizer; B Rosner; W Willett; C Belanger
Journal:  J Natl Cancer Inst       Date:  1982-04       Impact factor: 13.506

2.  Malignant melanoma and exposure to fluorescent lighting at work.

Authors:  V Beral; S Evans; H Shaw; G Milton
Journal:  Lancet       Date:  1982-08-07       Impact factor: 79.321

3.  Cutaneous melanoma in relation to exogenous hormones and reproductive factors.

Authors:  E A Holly; N S Weiss; J M Liff
Journal:  J Natl Cancer Inst       Date:  1983-05       Impact factor: 13.506

4.  Cutaneous factors related to the risk of malignant melanoma.

Authors:  V Beral; S Evans; H Shaw; G Milton
Journal:  Br J Dermatol       Date:  1983-08       Impact factor: 9.302

5.  Malignant melanoma and oral contraceptive use among women in California.

Authors:  V Beral; S Ramcharan; R Faris
Journal:  Br J Cancer       Date:  1977-12       Impact factor: 7.640

6.  A case-control study of the possible association between oral contraceptives and malignant melanoma.

Authors:  S A Adam; J K Sheaves; N H Wright; G Mosser; R W Harris; M P Vessey
Journal:  Br J Cancer       Date:  1981-07       Impact factor: 7.640

  6 in total
  16 in total

Review 1.  Risk for malignant tumors after oral contraceptive use: is it related to organ size while taking the pill?

Authors:  H Olsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

2.  Age at first birth and melanoma risk: a meta-analysis.

Authors:  Zhengyong Li; Mingjin Gu; Ying Cen
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 3.  Oral contraceptive use and risk of cutaneous malignant melanoma in a case-control study of French women.

Authors:  M G Lê; P A Cabanes; V Desvignes; M F Chanteau; N Mlika; M F Avril
Journal:  Cancer Causes Control       Date:  1992-05       Impact factor: 2.506

4.  Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials.

Authors:  Jean Y Tang; Katrina M Spaunhurst; Rowan T Chlebowski; Jean Wactawski-Wende; Elizabeth Keiser; Fridtjof Thomas; Matthew L Anderson; Nathalie C Zeitouni; Joseph C Larson; Marcia L Stefanick
Journal:  J Natl Cancer Inst       Date:  2011-08-30       Impact factor: 13.506

Review 5.  The relationship between oral contraceptive use, cancer and vascular disease.

Authors:  C La Vecchia; S Franceschi; P Bruzzi; F Parazzini; P Boyle
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

6.  Oral contraceptive use and risk of cutaneous malignant melanoma.

Authors:  J R Palmer; L Rosenberg; B L Strom; S Harlap; A G Zauber; M E Warshauer; S Shapiro
Journal:  Cancer Causes Control       Date:  1992-11       Impact factor: 2.506

7.  Aetiological factors in cutaneous malignant melanomas seen at a UK skin clinic.

Authors:  C M Bell; C M Jenkinson; T J Murrells; R G Skeet; J D Everall
Journal:  J Epidemiol Community Health       Date:  1987-12       Impact factor: 3.710

8.  Oral contraceptives and malignant melanoma.

Authors:  P C Hannaford; L Villard-Mackintosh; M P Vessey; C R Kay
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

9.  Risk of malignant melanoma in relation to drug intake, alcohol, smoking and hormonal factors.

Authors:  J Westerdahl; H Olsson; A Måsbäck; C Ingvar; N Jonsson
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

10.  Reproductive factors, oral contraceptives and risk of malignant melanoma: Western Canada Melanoma Study.

Authors:  R P Gallagher; J M Elwood; G B Hill; A J Coldman; W J Threlfall; J J Spinelli
Journal:  Br J Cancer       Date:  1985-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.